Thus, these clinical trials suggest that monotherapies targeting CDK4/6 are not very effective treatment for lung cancer patients, and CDK4/6 inhibitors combining with other drugs rank as a reasonable strategy. The gene discussed is CDK4; the disease is lung carcinoma.